RxDoctor Payments Data

Judith McKenzie, MD

Family Medicine · Newport News, VANPI 1215902887

Payments from drug & device makers

$981in general payments, 2019–2025

Across 47 payments — averaging $20.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$354
  • Abbott$213
  • GSK$137
  • Dexcom, Inc.$47
  • Novartis$47
  • Inspire Medical Systems, Inc.$39
  • plus $143 from 7 others

What the payments were for

  • Travel & lodging$384%
  • Food & beverage$92494%
  • Education$192%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$981 in reported general payments places this provider in the 65th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$58,680
Medicare patients
345
Services billed
882

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide58$59,630
OzempicSemaglutide45$48,549
JanuviaSitagliptin Phosphate63$47,923
TrulicityDulaglutide24$32,006
XareltoRivaroxaban28$28,025
EliquisApixaban24$20,807
Janumet XrSitagliptin Phos/Metformin Hcl23$16,711
Breo ElliptaFluticasone/Vilanterol17$13,213
FarxigaDapagliflozin Propanediol23$12,453
SymbicortBudesonide/Formoterol Fumarate22$9,638
LinzessLinaclotide17$9,297
Lantus SolostarInsulin Glargine,hum.Rec.Anlog42$6,738
Combivent RespimatIpratropium/Albuterol Sulfate12$6,086
PremarinEstrogens, Conjugated11$5,503
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$3,788

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$25$48,54945 claims
PfizerEliquis, Premarin$16$26,31035 claims
GSKBreo Ellipta$137$13,21317 claims
AbbVieLinzess, Synthroid$354$12,42860 claims
Boehringer IngelheimCombivent Respimat, Jentadueto Xr$19$9,15724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Newport News

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →